Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients
Despite improvements in 2nd-generation cBTKi cardiotoxicity, patients with CLL/SLL receiving cBTKis have a considerable cardiovascular disease burden. These findings highlight the unmet need for CLL/SLL treatment options with improved efficacy and safety profiles.
Authors
- Hayden W. Hyatt (ORCID: https://orcid.org/0000-0001-8075-5670)
- David Dingli (ORCID: https://orcid.org/0000-0001-7477-3004)
- Enrico De Nigris
- Ian Weimer (ORCID: https://orcid.org/0000-0002-2725-7207)
- Mavis Obeng‐Kusi (ORCID: https://orcid.org/0000-0001-6159-6782)
- Xuan Zhang (ORCID: https://orcid.org/0000-0002-3359-7283)
- Siyang Leng (ORCID: https://orcid.org/0000-0002-4852-7114)
- Weiqi Jiao (ORCID: https://orcid.org/0000-0003-3964-2185)
- Kunal Lodaya
- Mohammed Farooqui
- Halit O. Yapici (ORCID: https://orcid.org/0009-0003-2447-7962)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- WinnMed (US)
- MSD (UK) Limited (United Kingdom) (GB)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1080/14796694.2025.2600913
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00